کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5993539 | 1179817 | 2015 | 6 صفحه PDF | دانلود رایگان |
ObjectiveAlthough drug-eluting balloons (DEBs) have shown promising results treating de novo (DN) atherosclerotic lesions and appear to have been widely adopted in Europe, their long-term efficacy in the broad spectrum of femoropopliteal restenosis (RE) remains to be proven. The purpose of the study was to assess the efficacy of paclitaxel-DEBs in restenotic (stented and nonstented) vs DN stenotic femoropopliteal arteries.MethodsThe study prospectively enrolled 100 patients undergoing femoropopliteal endovascular intervention by DEB for RE or DN stenosis. Patients who received additive atherectomy were excluded. The primary end point was the primary patency (PP) rate at 12Â months. Secondary end points were sustained clinical improvement and clinically driven target lesion revascularization.ResultsDEBs were used to treat 105 limbs for intermittent claudication (82 [78%]) or critical limb ischemia (23 [22%]) in 100 patients. Of these, 111 lesions were DN stenosis (46 [41%]) or RE (65 [59%]). The overall PP was 86% at 6Â months and 74% at 12Â months. PP of DN stenosis was higher at 6Â months (93% vs 81%) and was significantly (PÂ = .021) better than RE at 12Â months (85% vs 68%). Sustained clinical improvement based on Rutherford classification was significant in both groups (PÂ < .001). Target lesion revascularization was significantly lower in DN stenosis compared with RE at 12Â months (15% vs 32%; PÂ = .021).ConclusionsDEB angioplasty is an effective therapy for DN femoropopliteal lesions. The results of DEB angioplasty for RE are inferior compared with DN stenosis after 12Â months. Nevertheless, results of DEB angioplasty for RE seem comparable with technically more demanding literature-derived strategies.
Journal: Journal of Vascular Surgery - Volume 61, Issue 2, February 2015, Pages 394-399